HCW Biologics (HCWB) vs Mustang Bio (MBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
HCW Biologics is the larger company by market cap ($3.6 million vs $3.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCWB | MBIO |
|---|---|---|
| Share price | $1.60 | $0.4001 |
| Market cap | $3.58M | $3.03M |
| 1-day change | +4.58% | -2.44% |
| EPS (TTM) | $-21.01 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.30 | $1.69 |
| 52-week low | $1.50 | $0.3802 |
| Distance from 52-week high | -94.14% | -76.33% |
| Analyst consensus | buy | — |
| Avg. price target upside | +2900.00% | — |
| Average volume | 381.72K | 28.87K |
| Shares outstanding | 2.24M | 6.73M |
| Employees | 35 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
HCWB vs MBIO FAQ
Which is bigger, HCW Biologics or Mustang Bio?
HCW Biologics (HCWB) is larger, with a market capitalization of $3.58M compared with $3.03M for Mustang Bio (MBIO).
Are HCW Biologics and Mustang Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.